Daniel Zurr, Ph.D. President and Chief Executive Officer
Daniel Zurr Ph.D., CEO, Founder and Director, former President of Plantex Ikapharm (currently part of the Teva Group). Dr. Daniel Zurr founded Quark in 1993 and is currently CEO of the Company. Dr. Zurr also currently serves as a Director of QBI. Dr. Zurr has vast experience in senior research and business management in the chemical and pharmaceutical industries. Prior to establishing QBI, Dr. Zurr was the CEO of Plantex-Ikapharm, then the second largest pharmaceutical company in Israel with more than 300 employees and marketing offices in the United States, Europe and Japan, focused in the field of bulk active ingredients and finished dosage pharmaceuticals. During Dr. Zurr’s tenure, Plantex Ikapharm, now part of the Teva group of companies, became the first Israeli company ever to be inspected and approved by the FDA. In the early eighties, Dr. Zurr served as the Director of Licensing at G.D. Searle in Skokie, Illinois, where he was responsible for the major collaborative agreement between G.D. Searle and Meiji Seika Kaisha (Tokyo), involving the licensing of several drugs and recombinant DNA technology transfer. Dr. Zurr was also responsible for numerous other agreements, including those with Bayer AG (Leverkusen), Ono Pharmaceutical (Osaka) and May and Baker (London). Dr. Zurr received his M.Sc. at the Hebrew University of Jerusalem and his Ph.D. from the Imperial College University of London under the guidance of the Nobel Laureate Professor D.H.R. Barton.

Rami Skaliter, Ph.D. Chief Operating Officer
Rami Skaliter PhD., COO. Dr. Rami Skaliter joined Quark in 1995. Since then he has assumed different executive roles including Vice President and Executive Vice President of Research & Development. Under his leadership, Quark’s research and development unit generated most of its current product pipeline. Dr. Skaliter obtained his B.Sc. in Biology at the Ben-Gurion University and his M.Sc. and Ph.D. in Biochemistry at the Weizmann Institute in Israel. He specialized in the biochemistry of replication and mutagenesis mechanisms. Between 1993 and 1995, prior to joining Quark, Dr. Skaliter completed his post-doctoral fellowship at Stanford University. Dr. Skaliter previous experience included managing large organizations of up to several thousand people which has played a key role in Quark’s benefit.

Shai Erlich, Ph.D., Chief Development Officer
Shai Erlich, Ph.D.,Chief Development Officer. Dr. Erlich joined Quark in 1999 and has assumed since then several executive positions including Portfolio Management and Product Development Strategic Planning. He currently heads all product development activities in Quark as Senior Vice President of Pharmaceutical Development. Under his tenure, Dr. Erlich and his team successfully ensured insertion and progress of most of Quark’s current products along the development pipeline. Dr. Erlich completed his studies at the School of Medicine at Ben Gurion University in Israel, and holds an M.Sc. in cancer genetics from the department of human genetics, Tel Aviv University, and a Ph.D. in Gene Therapy from the department of human genetics, Mt Sinai Graduate School for Biomedical Sciences at the Mt Sinai School of Medicine, New York.

Elena Feinstein, Ph.D., Chief Scientific Officer
Elena Feinstein, MD, PhD., Chief Scientific Officer. Dr. Feinstein joined Quark in 1998. She held increasing senior positions, including Senior Scientist, Director of Research and Development, Vice President of Research and Vice President of Technology Development. Dr. Feinstein has been responsible for biology research and candidate discovery between 1998-2001 and of biological research and proof on concept studies with Quark product candidates since 2003. Prior to joining Quark, Dr Feinstein worked for about 12 years in the Weizmann Institute of Science as Doctoral Fellow, Post-Doctoral Fellow, Scientist and Senior Staff Scientist. She has a 2-year practical clinical experience from Clinical Pediatric Hospital No.1 in Moscow, Russia. Dr. Feinstein obtained her MD degree from the 2nd Moscow Medical Institute (Moscow Medical University) and completed her Ph.D. studies (Bondi Prize for Excellence) in the Department of Chemical Immunology, the Weizmann Institute of Science, Rehovot, Israel. Dr. Feinstein is a leading or senior author of numerous publications in peer-reviewed journals among which several were published in the are Science magazine and Nature. Dr. Feinstein is an inventor on numerous patent applications and awarded patents.

Juliana Friedmann, M.Sc., Senior Vice President of Strategy and Planning
Juliana Friedmann, M.Sc., Senior Vice President of Strategy and Planning. Juliana Friedmann joined Quark (QBI) in 1998. Throughout her career of over 20 years, Ms. Friedmann’s experience has focused on intellectual property, marketing, business development and strategic planning activities in the chemical and pharmaceutical industries. In 1983, Ms. Friedmann joined Dead Sea Bromine, of Israel Chemicals Ltd. (ICL), the largest chemical conglomerate in Israel. From 1983 until she joined Quark in 1998, Ms. Friedmann held a number of progressively senior positions including managing organic fine chemical products serving the life science industries, a major biocide joint venture with the U.S. leader in the field and directing business and new product development activities. Previously Ms. Friedmann worked as a Patent Attorney in Milan, Italy, at one of Italy’s largest patent firms with offices in Germany. Ms. Friedmann received her Bachelor of Science degree in Chemical Engineering from Ben Gurion University, Israel, in 1975 and her Master of Science degree in 1977.

Smadar Shakked, C.P.A. Senior Vice President, Finance
Smadar Shakked, C.P.A., MBA, Vice President, Finance. Before joining Quark, Mrs. Shakked worked at the accountancy firm of PWC Kesselman and Kesselman, Israel, as Manager Auditor of private and public companies (specializing in the hi-tech industry) trading in Israel and on NASDAQ, managing financial reports, initial public offerings, tax returns, economic consulting. Mrs. Shakked holds a degree in Accounting and Economics from the Hebrew University of Jerusalem, Israel, and in 1994 obtained her Certified Public Accountant (CPA) license. Ms. Samira also holds an Executive MBA degree from Tel Aviv University.

James D. Thompson, Ph.D. Vice President Pharmaceutical Development
James D. Thompson, Ph.D., Vice President Pharmaceutical Development. Prior to joining Quark, Dr. Thompson was Director of Research & Development at Genta, Inc., and before this was Director, Biology Research at Ribozyme Pharmaceuticals/Sirna Therapeutics. Dr. Thompson received a BS in Biology from Temple University and a Ph.D. in Biological Chemistry from Hahnemann University in Philadelphia

Carlos Benaim, M.Sc., Vice President, Information Technologies
Carlos Benaim, M.Sc., Vice President, Information Technologies. Mr. Benaim joined Quark in 2002 after more than 13 years of experience in roles combining management and information technologies. Mr. Benaim held technical and managerial positions in organizations such as Global 500 PDVSA subsidiaries. Among other responsibilities, Mr. Benaim designs and implements Quark’s information technology strategies while also managing current corporate IT infrastructure and operation. In addition, he is responsible for advising research and development project managers on project management techniques and methodologies, ensuring usage of the best practices in the field. He is a permanent member of the Research and Development Project Management meetings and General Operation meetings. He holds a first degree in Computer Science and an M.Sc. in Management of Technology from M.I.T.